Pridopidine, which targets S1R and dopamine D2/D3 receptors, has undergone Phase 2 evaluation for levodopa-induced dyskinesia and Phase 3 trials for early Huntington’s disease (HD) [10,11]. This evidence concerns the gene TMBIM4 and Huntington disease.